The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Application of Botulinum Toxin in Pain Management

  • Sim, Woo-Seog (Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2011.01.24
  • Accepted : 2011.01.31
  • Published : 2011.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Botulinum toxin has been used for the treatment of many clinical disorders by producing temporary skeletal muscle relaxation. In pain management, botulinum toxin has demonstrated an analgesic effect by reducing muscular hyperactivity, but recent studies suggest this neurotoxin could have direct analgesic mechanisms different from its neuromuscular actions. At the moment, botulinum toxin is widely investigated and used in many painful diseases such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Further studies are needed to understand the exact analgesic mechanisms, efficacy and complications of botulinum toxin in chronic pain disorders.

Keywords

References

  1. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002; 18(Suppl 6): S142-6. https://doi.org/10.1097/00002508-200211001-00005
  2. Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009; 59: 366-81. https://doi.org/10.1590/S0034-70942009000300013
  3. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002; 18(Suppl 6): S119-24. https://doi.org/10.1097/00002508-200211001-00002
  4. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 2003; 4: 159-65. https://doi.org/10.1054/jpai.2003.435
  5. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60. https://doi.org/10.1002/mds.20531
  6. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
  7. Apostol C, Abdi S, Moeller-Bertram T, Smith HS, Argoff CE, Wallace M. Botulinum toxins for the treatment of pain. In: Current therapy in pain. Edited by Smith HS. Philadelphia, Saunders. 2009, pp 489-98.
  8. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002; 18(Suppl 6): S125-32. https://doi.org/10.1097/00002508-200211001-00003
  9. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006; 102: 509-16. https://doi.org/10.1213/01.ane.0000194447.46763.73
  10. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001; 91: 195-9. https://doi.org/10.1016/S0304-3959(01)00292-5
  11. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, Botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005; 25: 604-11. https://doi.org/10.1007/s00296-004-0485-6
  12. Fishman LM, Konnoth C, Rozner B. Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. Am J Phys Med Rehabil 2004; 83: 42-50. https://doi.org/10.1097/01.PHM.0000104669.86076.30
  13. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil 2004; 83: 198-202. https://doi.org/10.1097/01.PHM.0000113404.35647.D8
  14. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006; 125: 82-8. https://doi.org/10.1016/j.pain.2006.05.001
  15. von Lindern JJ, Niederhagen B, Berge S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003; 61: 774-8. https://doi.org/10.1016/S0278-2391(03)00153-8
  16. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005; 84: 649-54. https://doi.org/10.1097/01.phm.0000176339.73591.d7
  17. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001; 56: 1290-3. https://doi.org/10.1212/WNL.56.10.1290
  18. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain 2002; 18(Suppl 6): S155-62. https://doi.org/10.1097/00002508-200211001-00007
  19. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40: 445-50. https://doi.org/10.1046/j.1526-4610.2000.00066.x
  20. Silberstein SD, Gobel H, Jensen R, Elkind AH, Degryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26: 790-800. https://doi.org/10.1111/j.1468-2982.2006.01114.x
  21. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebocontrolled study. Cephalalgia 2004; 24: 838-43.
  22. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004; 44: 801-5. https://doi.org/10.1111/j.1526-4610.2004.04148.x
  23. Freund BJ, Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. Clin J Pain 2002; 18(Suppl 6): S163-8. https://doi.org/10.1097/00002508-200211001-00008
  24. Mahowald ML, Krug HE, Singh JA, Dykstra D. Botulinum toxin for osteoarticular pain. In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 295-306.
  25. Smith PP, Smith CP. Botulinum toxin in the treatment of chronic pelvic pain syndromes In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 257-68.
  26. Hallett M. Potential new therapeutic indications for botulinum neurotoxins. In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 367-72.

Cited by

  1. The pharmacological management of neuropathic pain vol.55, pp.6, 2012, https://doi.org/10.5124/jkma.2012.55.6.582
  2. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? vol.14, pp.1, 2013, https://doi.org/10.1186/1129-2377-14-92
  3. Treatment of Morton Neuroma with Botulinum Toxin A: A Pilot Study vol.33, pp.7, 2013, https://doi.org/10.1007/s40261-013-0090-0
  4. Effect of Hyaluronidase Addition to Lidocaine for Trigger Point Injection in Myofascial Pain Syndrome vol.16, pp.8, 2015, https://doi.org/10.1111/papr.12362
  5. Integrated Approach for Pain Management in Parkinson Disease vol.16, pp.4, 2016, https://doi.org/10.1007/s11910-016-0628-7
  6. A pharmacological treatment algorithm for localized neuropathic pain vol.32, pp.2, 2016, https://doi.org/10.1185/03007995.2015.1129321
  7. Subcutaneous Botulinum Toxin Injection for Post-Thoracotomy Pain Syndrome in Palliative Care: A Case Report pp.1938-2715, 2017, https://doi.org/10.1177/1049909117716460
  8. Use of botulinum toxin in musculoskeletal pain vol.2, pp.2046-1402, 2013, https://doi.org/10.12688/f1000research.2-52.v2
  9. Chronic orofacial pain animal models - progress and challenges vol.13, pp.10, 2018, https://doi.org/10.1080/17460441.2018.1524458
  10. Therapeutic Approaches of Botulinum Toxin in Gynecology vol.10, pp.4, 2018, https://doi.org/10.3390/toxins10040169
  11. Botulinum Toxin Treatment of Myofascial Pain: A Critical Review of the Literature vol.16, pp.5, 2012, https://doi.org/10.1007/s11916-012-0287-6
  12. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States vol.20, pp.3, 2016, https://doi.org/10.1007/s11916-016-0545-0
  13. The Benefit of Botulinum Toxin A in the Management of Central Post Stroke Pain: A Case Report vol.6, pp.6, 2011, https://doi.org/10.15406/jnsk.2017.06.00218
  14. Beyond the muscular effects – onabotulinumtoxinA injections for pain control in chronic knee osteoarthritis: a case report vol.11, pp.None, 2018, https://doi.org/10.2147/jpr.s159841
  15. Celiac plexus block with botulinum toxin in severe chronic pancreatitis—A case report vol.45, pp.4, 2011, https://doi.org/10.1111/jcpt.13180
  16. The effect of botulinum toxin A on patients with persistent idiopathic dentoalveolar pain—A systematic review vol.47, pp.9, 2011, https://doi.org/10.1111/joor.13053
  17. Effect of multiple injections of botulinum toxin into painful masticatory muscles on bone density in the temporomandibular complex vol.47, pp.11, 2011, https://doi.org/10.1111/joor.13087
  18. Effects of botulinum toxin A on endometriosis-associated pain and its related mechanism vol.22, pp.5, 2011, https://doi.org/10.3892/mmr.2020.11501
  19. Chronic Pain Treatment Strategies in Parkinson’s Disease vol.12, pp.3, 2011, https://doi.org/10.3390/neurolint12030014
  20. Botulinum Toxin Type A for Diabetic Peripheral Neuropathy Pain: A Systematic Review and Meta-Analysis vol.14, pp.None, 2011, https://doi.org/10.2147/jpr.s340390
  21. Botulinum toxin injections as salvage therapy is beneficial for management of patellofemoral pain syndrome vol.33, pp.1, 2011, https://doi.org/10.1186/s43019-021-00121-3
  22. Non-invasive Intrauterine Administration of Botulinum Toxin A Enhances Endometrial Angiogenesis and Improves the Rates of Embryo Implantation vol.28, pp.6, 2011, https://doi.org/10.1007/s43032-021-00496-4
  23. Botulinum Neurotoxins (BoNTs) and Their Biological, Pharmacological, and Toxicological Issues: A Scoping Review vol.11, pp.19, 2011, https://doi.org/10.3390/app11198849
  24. Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice vol.12, pp.None, 2011, https://doi.org/10.1016/j.toxcx.2021.100083
  25. Intraoperative Botulinum Toxin Chemodenervation and Analgesia in Abdominal Wall Reconstruction vol.28, pp.6, 2021, https://doi.org/10.1177/1553350620975253